occidiofungin

Occidiofungin is a first-in-class, nonribosomally synthesized cyclic glycolipopeptide antifungal compound originally isolated from Burkholderia contaminans MS14. It exhibits potent broad-spectrum activity against a wide range of fungal pathogens, including multidrug-resistant species such as Candida auris. Occidiofungin’s mechanism of action is unique among antifungals; it binds to actin in fungal cells and disrupts higher-order actin cable structures without affecting the polymerization or depolymerization of F-actin. This disruption leads to apoptosis in fungal cells, distinguishing it from existing antifungal classes that primarily target cell wall or membrane stability. Occidiofungin has demonstrated efficacy in animal models for systemic and vulvovaginal candidiasis and shows promise for other indications such as dermal and oral candidiasis. The drug is being developed by Sano Chemicals and has entered Phase 1 clinical trials for recurrent vulvovaginal candidiasis (RVVC) in adult women[2][3][5][6][7][8].

Other names

OCF001OCF-001OCF 001